Court Denies Renovaro Motion for an Expedited Trial in July
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/8/2026
- S&P 500, Nasdaq end lower as crude prices jump, chip stocks weigh
- Oil rises 4% on revived Middle East worries, Hurricane Isaias supply disruption
- Chipotle, Starbucks shares volatile after report of potential takeover
- Why Citi says the Fed could be setting up for a dovish surprise
- Alphabet shares rise as Google pushes Gemini deeper into enterprise AI
- Anthropic launches Claude Haiku 5.5 with tiered pricing structure
- CoreWeave stock drops on dilution fears and debt concerns
- Sportradar to sell Synergy Sports coaching unit for $170M
- Rezolve AI (RZLV) Reiterated at Overweight by Cantor Fitzgerald on Positioning as Key Component in E-Commerce Stack
- SpaceX to acquire Grain Management's 800 MHz spectrum portfolio
Court Denies Renovaro Motion for an Expedited Trial in July
May 27, 2025 8:35 AM EDTPITTSBURGH, May 27, 2025 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI), a leader in AI-driven drug discovery, today issued the following statement regarding its dispute with Renovaro, Inc.
Contrary to a press release issued by RENB, the Delaware Court of Chancery recently rejected RENBs request for an expedited, two-day trial in July. The Court reached this decision citing RENBs delay in bringing its action.Â
POAI fully intends to protect its rights and defend against the claims asserted by RENB that are premised on inaccurate allegations and lack any merit. The... More



